INTRODUCTION {#sec1-1}
============

Acquired Immunodeficiency Syndrome (AIDS), which threatens to cause a great plague in the present generation, was first identified in California in 1981. AIDS is a disease in which the body\'s immune system breaks down and is unable to fight off infections caused by human immunodeficiency virus (HIV). HIV infects human cells and uses the energy and nutrients provided by those cells to grow and reproduce, so it is necessary to take many medicines for longer periods of time. This can lead to an increase in noncompliance of drugs. This problem is very serious in case of drugs having shorter biological half-life because they must be taken more number of times. It is crucial for the success of AIDS therapy to maintain systemic drug concentration consistently above its target antiretroviral concentration throughout the course of the treatment.\[[@ref1][@ref2]\] Oral drug delivery systems have progressed from immediate release to site-specific delivery over a period of time. Every patient would always like to have an ideal drug delivery system possessing the two main properties, i.e. single dose or less frequent dosing for the whole duration of treatment and the dosage form must release the active drug directly at the site of action.\[[@ref3]\] Sustained release (SR) gastroretentive dosage forms (GRDF) enable prolonged and continuous input of the drug to stomach and upper parts of the gastrointestinal (GI) tract. These systems are designed to be retained in the stomach for longer period of time, and hence significantly prolong the gastric residence time of drugs. Therefore, different approaches have been proposed to retain the dosage form in the stomach, including bioadhesive systems, swelling and expanding systems, floating systems, and delayed gastric emptying devices.\[[@ref4]--[@ref6]\] Among these, the floating dosage form has been used most commonly. This technology is suitable for drugs with an absorption window in the stomach or in the upper part of the small intestine, drugs acting locally in the stomach, and for drugs that are poorly soluble or unstable in the intestinal fluid. The floating systems include single, multiple, and raft forming systems. The principle of these systems offers a simple and practical approach to achieve increased gastric residence time for the dosage form and sustained drug release. The present investigation is concerned about the development of mix matrix floating drug delivery systems by melt granulation technique that generates CO~2~, and thus reduces the density of the system in the stomach for prolonged period of time and releases the drug slowly at the desired rate. Stavudine is used as a part of highly active antiretroviral therapy. Stavudine, a nucleoside analog of thymidine, is phosphorylated using cellular kinases to the active metabolite, stavudine triphosphate. Stavudine triphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate thymidine triphosphate and by causing DNA chain termination following its incorporation into viral DNA.\[[@ref7]\] Stavudine is typically administered orally as a capsule and an oral solution. The drug has a very short half-life (1.5 h), thus necessitating frequent administration to maintain constant therapeutic drug levels. Formulation of extended release effervescent floating tablets of stavudine improves patient compliance and minimizes the dose-related side effects. Therefore, this study aims at formulating once a day floating mix matrix tablets using hydroxypropyl methylcellulose (HPMC) as the hydrophilic polymer and bees wax as the hydrophobic material release rate modifying polymer, and NaHCO~3~ and ethyl cellulose were used as the floating aid and release modifier.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials {#sec2-1}
---------

Stavudine was a gift from Emcure Pharmaceutical Ltd. (Pune, India). HPMC K15M and bees wax were purchased from Yarrow chemicals (Mumbai, India). Ethyl cellulose was purchased from SD Fine Chem. Ltd. (Mumbai, India). Lactose and talc were obtained from Chemdyes Corporation (Ahmedabad, India). Magnesium stearate and sodium bicarbonate were purchased from Shakti Chemicals (Mehsana, India).

Method {#sec2-2}
------

### Calculation for the dose of drug in the tablets {#sec3-1}

The total dose of stavudine for an SR formulation was calculated by the following four equations\[[@ref8]\] using available pharmacokinetic data from a design of one compartment model with simultaneous release of loading dose and a zero-order release, maintenance dose, as described by Robison and Eriksen:\[[@ref9]\]

K~0~ = D~i~K~e~...........(1)

D~m~ = K~0~T...........(2)

D~l~ = Di-K~0~T~p~.......(3)

D~t~ = D~l~+D~m~.......(4)

D~m~ = maintenance dose; T = time for sustained action; T~p~ = time to reach peak plasma concentration; elimination half-life of stavudine t~1/2~ = 0.8--1.5 h (average 1.175); time to reach peak plasma concentration (T~P~) = 1 h; initial dose (D~I~) = 25 mg.

Elimination rate constant (K~e~) = 0.693/t~1/2~

= 0.693/1.175

= 0.589 h

Zero-order release constant (K~0~ = D~I~ × K~e~

= 25 × 0.589

= 14.74 mg/h

Loading dose (D~l~) = D~I~ -- (K~0~ × T~P~)

= 25 -- (14.74 × 1)

= 25 -- 14.74

= 10.26 mg.

So, maintenance dose = total dose -- loading dose

= 40 mg -- 10.26 mg

= 29.74 mg.

Hence, the matrix tablet should contain a total dose of 40 mg for 12 h SR dosage form and it should release 25 -- 14.74 = 10.26 (25.62%) mg in the 1^st^ h like conventional dosage form and the remaining dose (40 -- 10.26) in remaining 11 h, i.e. 29.74 (74.35%) mg or 2.70 (1.08%) mg per hour up to 12 h.

Hence, the theoretical drug release profile can be generated using the above value which is shown in [Table 1](#T1){ref-type="table"}.

###### 

Theoretical profile of stavudine

![](IJPI-2-83-g001)

### Preliminary screening {#sec3-2}

Preliminary screening was carried out using three different grades of HPMC K~4~M, three different concentrations of sodium bicarbonate, and three different concentrations of bees wax to select proper total floating time, floating lag time, and sustain the release up to 12 h. The formulas of batch HF1 to HF3 are shown in [Table 2](#T2){ref-type="table"}. NF1 to NF3 are shown in [Table 3](#T3){ref-type="table"}. BF1 to BF3 are shown in [Table 4](#T4){ref-type="table"}. Tablets prepared using different polymers were tested for total floating time, floating lag time, % drug content, weight variation, hardness, friability, *in vitro* drug release, etc.

###### 

Composition for preliminary screening of the polymer (different grades of HPMC) for total floating time

![](IJPI-2-83-g002)

###### 

Formulation of stavudine floating tablet using different amounts of sodium bicarbonate

![](IJPI-2-83-g003)

###### 

Formulation of stavudine floating tablet using different amounts of polymer and wax

![](IJPI-2-83-g004)

Optimization by 2^3^ full factorial design {#sec2-3}
------------------------------------------

A 2^3^ randomized full factorial design was used in the present study. In this design, three independent factors were evaluated, each at two levels, and experimental trials were performed for all eight possible combinations. The concentrations of bees wax (X~1~), HPMC K4M (X~2~), and ethyl cellulose (X~3~) were chosen as independent variables in 2^3^ full factorial design. *In vitro* drug release values at 1 h (Q~1~), 6 h (Q~6~), and 12 h (Q~12~) were taken as dependent variables. The formulation layout for the factorial design batches (F1--F8) is shown in Table [5a](#T5){ref-type="table"} and [b](#T6){ref-type="table"}. Prepared tablets were evaluated for weight variation, hardness, thickness, % drug content, friability, buoyancy lag time, and *in vitro* drug release.

###### 

Formulation layout

![](IJPI-2-83-g005)

###### 

Compositions of formulations of factorial design

![](IJPI-2-83-g006)

Preparation of stavudine floating tablets by melt granulation {#sec2-4}
-------------------------------------------------------------

Bees wax was melted in a large Petri dish at 60°C and the required quantity of stavudine was added to the melted mass. Previously prepared geometric mixture of HPMC K4M, sodium bicarbonate, and filler was added to the molten stavudine--beeswax and stirred well to mix. The mass was removed from the hot plate and subjected to scraping until it attained room temperature. The coherent mass was passed through 60 \#. The granules was collected and mixed with talc (2%) and magnesium stearate (1%). The lubricated blend was compressed using round tooling on a Rimek-I rotary tablet machine (Karnavati Engineering, Kadi, India). Compression was adjusted to obtain tablets with hardness in the range of 2--3 kg/cm^2^.

Evaluation of tablets {#sec2-5}
---------------------

The prepared tablets were evaluated for weight variation, friability, hardness, content uniformity, *in vitro* dissolution study, floating lag time, and total floating time.

### Weight variation {#sec3-3}

Twenty tablets were selected at random, weighed, and the average weight was calculated. Not more than two of the individual weights should deviate from the average weight by more than 7.5%.

### Friability {#sec3-4}

For each formulation, pre-weighed tablet sample (20 tablets) was placed in the Roche Friability test apparatus (USP) EF-02 (Electrolab, Mumbai, India), which was then operated for 100 revolutions. The tablets were deducted and reweighed. Conventional compressed tablets that lose \<0.5--1% of their weight were considered acceptable.

### Hardness {#sec3-5}

Hardness of tablet was determined before and after sintering using Monsanto Hardness Tester.

### Content uniformity {#sec3-6}

The drug content in each formulation was determined by triturating ten tablets and a quantity of powder equivalent to the mass of one tablet was extracted with pH 1.2 buffer and the solution was filtered through 0.45 *μ*m membranes. The absorbance was measured at 266 nm after suitable dilution using UV visible spectrophotometer at λmax of 266 nm and the amount of stavudine was found using the calibration curve method.

### In vitro floating studies {#sec3-7}

The *in vitro* floating of the tablets was studied at 37 ± 0.5°C in 100 ml of 0.1 N HCl. The time duration of tablet floatation was observed visually.\[[@ref10][@ref11]\]

### In vitro dissolution study {#sec3-8}

The in vitro dissolution study of stavudine tablets was performed using USP apparatus (model TDT-08T; Electrolab, Mumbai, India) fitted with paddle (50 rpm) at 37 ± 0.5°C using simulated gastric fluid (SGF) (pH 1.2; 900 ml) as the dissolution medium. At predetermined time intervals, 10-ml samples were withdrawn, filtered through a 0.45-*μ*m membrane filter, diluted, and assayed at 266 nm using a Shimadzu UV-1800 double-beam spectrophotometer (Shimadzu, Kyoto, Japan). Cumulative percentage release (CPR) of the drug was calculated using an equation obtained from a calibration curve.

Drug--excipient interaction compatibility study {#sec2-6}
-----------------------------------------------

### FT-IR study {#sec3-9}

Fourier transform infrared (FT-IR) technique was used to study the physical and chemical interaction between the drug and excipients used. FT-IR spectra of pure drug and floating tablet were recorded using KBr mixing method on FT-IR instrument available at central instrument laboratory of the institute (FT-IR-1700, Shimadzu).

### Differential Scanning Calorimetry (DSC) {#sec3-10}

DSC was used to study physical and chemical interaction between the drug and excipients used. DSC spectra of pure drug and drug composite mixture were recorded on DSC-60 instrument available at central instrument laboratory of the institute (DSC-60, Shimadzu).

### Kinetic modeling of dissolution data {#sec3-11}

The dissolution profile of all factorial batches was fitted to various models such as zero order, first order, Higuchi,\[[@ref12]\] Hixon Crowell,\[[@ref13]\] and Korsemeyer and Peppas\[[@ref14]\] to ascertain the kinetics of drug release. The method described by Korsemeyer and Peppas was used to describe the mechanism of drug release.

### Short term stability study {#sec3-12}

To determine the change in *in vitro* release profile and on storage, a short-term stability study of the optimal batch was performed at 40°C in a humidity jar with 75% relative humidity (RH). Samples were withdrawn at 1 month interval and evaluated for any change in *in vitro* drug release pattern.\[[@ref15]\]

RESULTS AND DISCUSSION {#sec1-3}
======================

Results of preliminary screening {#sec2-7}
--------------------------------

The evaluation results for different batches showed that batch HF1 which contained HPMC K4M (30%) gave maximum total floating time of more than 12 h \[[Table 2](#T2){ref-type="table"}\]. Hence, HPMC K4M was selected for further study. NF1 which contained 5% sodium bicarbonate gave a floating lag time of 137 sec and a total floating time of more than 12 h \[[Table 3](#T3){ref-type="table"}\]. Hence, 5% sodium bicarbonate was selected for further study. BF1 which contained 15% bees wax gave *in vitro* drug release of 95.75% \[[Table 4](#T4){ref-type="table"}\]. Hence, 15% bees wax selected for further study. Final prototype formulation is shown in [Table 6](#T7){ref-type="table"} which was considered in full factorial design.

###### 

Prototype formulation of stavudine floating tablet

![](IJPI-2-83-g007)

Results of full factorial design {#sec2-8}
--------------------------------

The average weight of the tablet was found to be between 192.39 mg and 198.81 mg. The maximum variation from average was found to be ±2.30% from all the formulations. Hardness of the tablets for all the formulations was found to be between 2 and 3 kg/cm^2^, with an average of 2.34 kg/cm^2^. The percentage deviation in hardness was 0.265 kg/cm^2^. Percentage friability for all formulations was found to be between 0.02 and 0.91%, with an average of 0.48%. Percentage drug content for all formulations was found to be between 97.00 and 101.10%. It was concluded that there was no loss of drug. Thickness of all the formulations was found to be between 1.80 and 2.30 mm. All these results are shown in [Table 7](#T8){ref-type="table"}.

###### 

Evaluation parameter of factorial batches

![](IJPI-2-83-g008)

*In vitro* drug release studies indicated that the drug release was higher in case of F1, F2, and F7. It indicates that as the concentration of bees wax increase in formulation the drug release decrease. Batch F7 showed the maximum drug release at 12 h, whereas batch F4 showed the minimum drug release at 12 h, as shown in [Table 8](#T9){ref-type="table"}.

###### 

*In vitro* drug release profile of factorial batches

![](IJPI-2-83-g009)

The dissolution profile of all factorial batches was fitted to various models such as zero order, first order, Higuchi, Hixon Crowell, and Korsemeyer and Peppas to ascertain the kinetics of drug release \[[Table 9](#T10){ref-type="table"}\]. For batches F2, F3, F4, F6, and F7, the values of n were 0.505, 0.506, 0.5091, 0.5199, and 0.545, respectively, indicating non-Fickian release; whereas for batches F1, F5, and F8, the values of n were 0.457, 0.269, and 0.487, respectively, indicating Fickian release. F7 batch gave zero-order release.

###### 

Kinetic treatment of dissolution data

![](IJPI-2-83-g010)

Dissolution data of all batches were subjected to find f~2~ similarity for the selection of optimum batch. Theoretical profile of stavudine was taken as reference. F7 batch showed maximum similarity (70.91) compared with other batches \[[Table 10](#T11){ref-type="table"}\]. Hence, formulation F7 was optimized based on the highest f~2~ similarity (70.91) it showed zeroorder drug release.

###### 

Comparison of *in vitro* drug release after stability study

![](IJPI-2-83-g011)

Drug--excipient compatibility study was carried out using FT-IR 1700 (Shimadzu) and DSC-60 (Shimadzu). Drug--excipient interaction plays a vital role in the release of drug from formulation. The drug exhibits carbonyl peak (C=O) at 1647.10 cm^--1^, alkyl peak (=C--H) at 3024.18 cm^--1^, and carbonyl amide group peak (N--H) at 3417.63 cm^--1^. It was observed that there were no changes in these main peaks in the IR spectra of a mixture of drug and excipient \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].

![FT-IR spectrum of stavudine](IJPI-2-83-g012){#F1}

![FT-IR spectrum of stavudine & excipients](IJPI-2-83-g013){#F2}

DSC thermograms were obtained for pure stavudine and mix matrix floating tablet containing stavudine and other excipients. Pure powdered stavudine showed a melting endotherm at 172.10°C \[[Figure 3](#F3){ref-type="fig"}\]. DSC thermograms of floating tablet showed the melting peak of the drug at 169.36°C \[[Figure 4](#F4){ref-type="fig"}\]. There was no significant difference in the melting point of drug in both samples. It indicates that the drug was present in its characteristic physical and chemical form. It was compatible with all the excipients present in the tablet and there was no major interaction of the drug with the excipients.

![DSC thermogram of stavudine](IJPI-2-83-g014){#F3}

![DSC thermogram of stavudine mix matrix floating tablet](IJPI-2-83-g015){#F4}

Stability study was carried out by storing optimized formulation at 40 ± 2°C and 75 ± 5% RH for 1 month. At the end of the studies, samples were analyzed for the drug content, *in vitro* drug release, and floating lag time. There was not any change in morphological condition during the stability study and also not any measurable change in the remaining parameter, as shown in [Table 7](#T8){ref-type="table"}. *In vitro* drug release was 98.44% after 12 h \[[Figure 5](#F5){ref-type="fig"}\]. Similarity factor of the batch after stability study was 77.09, which was comparable to the initial drug release profile.

![Comparison of release profile initially and after stability studies](IJPI-2-83-g016){#F5}

CONCLUSION {#sec1-4}
==========

It can be concluded from this study that the combined mix matrix system containing hydrophobic and hydrophilic polymer minimized the burst release of drug from the tablet and achieved a drug release by zero-order kinetics, which is practically difficult with only hydrophilic matrix. Bees wax used as hydrophobic material and HPMC K4M as hydrophilic material gave zero-order release of stavudine mix matrix floating tablet. Ethyl cellulose and sodium bicarbonate were used as floating enhancers and gave a total floating time of more than 12 h. From the regression analysis, insignificant factors were omitted. Formulation F7 was selected as an optimum formulation as it showed more similarity in dissolution profile with theoretical profile (similarity factor, f~2~ = 70.91). The dissolution of batch F7 can be described by zero-order kinetics (R^2^ = 0.9936) with anomalous (non-Fickian) diffusion as a release mechanism (n = 0.545). There was no difference observed in the release profile after temperature sensitivity study at 40°C/75% RH for 1 month.
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